Compare BIOA & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIOA | ORIC |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | 62 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 757.0M | 837.3M |
| IPO Year | N/A | 2020 |
| Metric | BIOA | ORIC |
|---|---|---|
| Price | $16.85 | $9.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | ★ $51.50 | $19.73 |
| AVG Volume (30 Days) | 375.2K | ★ 2.4M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $720.93 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.79 | $4.52 |
| 52 Week High | $24.00 | $14.93 |
| Indicator | BIOA | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 39.65 |
| Support Level | $15.59 | $7.68 |
| Resistance Level | $21.29 | $11.22 |
| Average True Range (ATR) | 1.31 | 0.62 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 25.48 | 7.79 |
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.